Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia

Patients with Chronic Lymphocytic Leukemia (CLL) have a 29- to 36-fold increased risk of invasive pneumococcal disease (IPD) compared to healthy adults. Therefore, most guidelines recommend vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) followed 2 months later by the 23-valen...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Sabine Haggenburg, Hannah M. Garcia Garrido, Iris M. J. Kant, Hanneke M. Van der Straaten, Fransien De Boer, Sabina Kersting, Djamila Issa, Doreen Te Raa, Hein P. J. Visser, Arnon P. Kater, Abraham Goorhuis, Koen De Heer
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2023-07-01
Edice:	Vaccines
Témata:	chronic lymphocytic leukemia pneumococcal vaccination immunogenicity antibody response
On-line přístup:	https://www.mdpi.com/2076-393X/11/7/1201
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!